AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
FDA revises Evra safety labeling due to increased estrogen levels
Patch may expose users to about 60% more estrogen than 35 mcg pill
Get ready to discuss questions about the safety of the Evra contraceptive patch (Ortho-McNeil Pharmaceutical, Raritan, NJ) now that the Food and Drug Administration (FDA) has revised the transdermal contraceptive's labeling. The labeling change includes an addition to the drug's warning section to note that the patch exposes women to higher levels of estrogen than most birth control pills. Your patients now will be reading the new bolded warning:
"Hormones from patches applied to the skin get into the blood stream and are removed from the body differently than hormones from birth control pills taken by mouth. You will be exposed to about 60% more estrogen if you use Ortho Evra than if you use a typical birth control pill containing 35 mcg estrogen. In general, increased estrogen exposure may increase the risk of side effects. However, it is not known if there are differences in the risk of serious side effects based on the differences between Ortho Evra and a birth control pill containing 35 mcg estrogen. Talk to your health care provider about how this information relates to your use of Ortho Evra."1
The pharmacokinetic profile for the patch differs from that of oral contraceptives in that it has higher steady state concentrations and lower peak concentrations. Since the level of estrogen fluctuates…
Source: HighBeam Research, FDA revises Evra safety labeling due to increased estrogen levels.